Healthcare Business Recap: Santarus’s Good NEWS, AstraZeneca Issues BONDS

Santarus, Inc. (NASDAQ:SNTS) reports that an advanced evaluation of its investigational antibiotic Rifamycin SV MMX met its primary endpoint in the treatment of travelers’ diarrhea. In response, Stifel Nicolaus raises its price target from $8 to $11 on the firm’s share, and also because of its successful appeal against Par Pharmaceutical Companies, Inc. (NYSE:PRX). The analyst believes that Zegerid will bring Santarus an additional $35 million to $45 million in yearly sales as a result of the court decision, and thus keeps its Buy.

Don’t Miss: Will Pfizer and Johnson & Johnson Get a SECOND CHANCE With Alzheimer’s Drug?

AstraZeneca Group plc (NYSE:AZN) has issued $2 billion worth of bonds, which comprises $1 billion of seven-year paper with a coupon of 1.95 percent and $1 billion of 30-year debt at 4 percent. Moody’s could rate the bonds at A1, according to Bloomberg. The firm will use the proceeds to refinance other debt and for general corporate purposes, as well.

Mediware Information Systems, Inc. (NASDAQ:MEDW) will sell itself to the private equity firm Thoma Bravo at $22 per share in cash, which represents a bonus of 40 percent over Tuesday’s close. close.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>